Literature DB >> 10412372

An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer.

L Gelman1, J C Fruchart, J Auwerx.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors and have been initially described as molecular targets for compounds which induce peroxisome proliferation. The interest of researchers for PPARs increased dramatically when these receptors were shown to be directly activated by a number of medically relevant compounds. These compounds include: the fibrate class of hypolidemic drugs, the thiazolidinediones, which are insulin sensitizers used as orally active antidiabetic agents, certain non-steroidal anti-inflammatory drugs (NSAIDs), and naturally occurring fatty acid-derived molecules. Rapidly, it was demonstrated that PPARs are key regulators of lipid homeostasis and provide a molecular link between nutrition and gene regulation. Recently, detailed studies of PPAR expression profiles in different tissues pointed to the roles these receptors play in inflammation control and cell proliferation. In this review we will focus on the new insights gained into these two areas and we will also discuss our current knowledge of the regulation of PPAR transcriptional activity by cofactors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10412372     DOI: 10.1007/s000180050345

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  39 in total

1.  Effects of peroxisome proliferators on the thymus and spleen of mice.

Authors:  Q Yang; Y Xie; J W Depierre
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

2.  HRASLS3 is a PPARgamma-selective target gene that promotes adipocyte differentiation.

Authors:  Sarah Hummasti; Cynthia Hong; Steven J Bensinger; Peter Tontonoz
Journal:  J Lipid Res       Date:  2008-07-29       Impact factor: 5.922

3.  Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1.

Authors:  Raquel Grau; Carmen Punzón; Manuel Fresno; Miguel A Iñiguez
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

4.  Therapeutic Implications of PPARgamma in Human Osteosarcoma.

Authors:  Eric R Wagner; Bai-Cheng He; Liang Chen; Guo-Wei Zuo; Wenli Zhang; Qiong Shi; Qing Luo; Xiaoji Luo; Bo Liu; Jinyong Luo; Farbod Rastegar; Connie J He; Yawen Hu; Barrett Boody; Hue H Luu; Tong-Chuan He; Zhong-Liang Deng; Rex C Haydon
Journal:  PPAR Res       Date:  2010-02-16       Impact factor: 4.964

5.  Characterization of the adipose tissue atrophy induced by peroxisome proliferators in mice.

Authors:  Yi Xie; Qian Yang; B Dean Nelson; Joseph W DePierre
Journal:  Lipids       Date:  2002-02       Impact factor: 1.880

6.  The peroxisome proliferator phenylbutyric acid (PBA) protects astrocytes from ts1 MoMuLV-induced oxidative cell death.

Authors:  Na Liu; Wenan Qiang; Xianghong Kuang; Philippe Thuillier; William S Lynn; Paul K Y Wong
Journal:  J Neurovirol       Date:  2002-08       Impact factor: 2.643

7.  Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas.

Authors:  Chuanbing Zang; Marlies Wächter; Hongyu Liu; Maximilian G Posch; Martin H Fenner; Christine Stadelmann; Andreas von Deimling; Kurt Possinger; Keith L Black; H Phillip Koeffler; Elena Elstner
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

Review 8.  Diet, fatty acids, and regulation of genes important for heart disease.

Authors:  John P Vanden Heuvel
Journal:  Curr Atheroscler Rep       Date:  2004-11       Impact factor: 5.113

9.  Gene expression profile after peroxisome proliferator activator receptor-gamma ligand administration in dextran sodium sulfate mice.

Authors:  Atsushi Nakajima; Koichiro Wada; Kazufumi Katayama; Lawrence Saubermann; Emi Osawa; Hajime Nagase; Norio Ueno; Nobuyuki Matsuhashi; Hiroyuki Aburatani
Journal:  J Gastroenterol       Date:  2002-11       Impact factor: 7.527

10.  Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.

Authors:  P J Simpson-Haidaris; S J Pollock; S Ramon; N Guo; C F Woeller; S E Feldon; R P Phipps
Journal:  PPAR Res       Date:  2010-02-28       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.